Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.
about
Functional changes in pulmonary arterial endothelial cells associated with BMPR2 mutationsMolecular pathogenesis of pulmonary arterial hypertensionUpregulated genes in sporadic, idiopathic pulmonary arterial hypertension.BMPR2 spruces up the endothelium in pulmonary hypertensionPathobiology of pulmonary arterial hypertension and right ventricular failureBMPs and their clinical potentialsPrinciples of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in diseaseThe molecular genetics and cellular mechanisms underlying pulmonary arterial hypertensionA comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?The genetics of pulmonary arterial hypertensionPotential contribution of phenotypically modulated smooth muscle cells and related inflammation in the development of experimental obstructive pulmonary vasculopathy in ratsPulmonary vascular disease related to hemodynamic stress in the pulmonary circulation.Novel signaling pathways in pulmonary arterial hypertension (2015 Grover Conference Series)AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertensionSM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesisAbnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertensionBone morphogenetic protein 4 enhances canonical transient receptor potential expression, store-operated Ca2+ entry, and basal [Ca2+]i in rat distal pulmonary arterial smooth muscle cellsHypoxia induces alteration of bone morphogenetic protein receptor signaling in pulmonary artery endothelial cellDownregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertensionPGC1α-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertensionInflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant miceA brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.Pulmonary arterial hypertension: the clinical syndrome.BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production.MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension.Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva.Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.Inflammation and immunity in the pathogenesis of pulmonary arterial hypertensionHeritable forms of pulmonary arterial hypertension.Role of somatic mutations in vascular disease formation.Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy.BMP type II receptors have redundant roles in the regulation of hepatic hepcidin gene expression and iron metabolismSomatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension.Divergent effects of BMP-2 on gene expression in pulmonary artery smooth muscle cells from normal subjects and patients with idiopathic pulmonary arterial hypertension.An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.Interleukin 13- and interleukin 17A-induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollutionNew perspectives for the treatment of pulmonary hypertensionHeterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension.Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats.
P2860
Q24303490-57942887-94EA-4D06-AD85-072E86CF8843Q24634317-504DAC9E-0E65-4770-A07D-18CE9A69D461Q25255715-E567383D-2C43-404B-9960-12FA7159C647Q26786834-7C82F9DF-6FB5-45F3-9F7C-826E8BD41E53Q26821779-DB838312-ED57-470D-8ACA-57A96CE47052Q26824827-CF78F7B4-4798-49C1-9376-F7885C86FFE4Q26859449-EC8B765C-3FF1-4879-B93F-D477795E9EF4Q26992278-85FFD8D0-FDA9-439E-8948-E8B304383413Q27026643-12922AD6-FB5C-4EA2-9EB8-0BA13CB8A9BFQ27027507-B151E6A6-5A02-417A-AB18-9C2079494084Q27313498-615D653E-35C4-461D-912D-5DFA30D3B3C6Q27687091-54732AC3-1673-4966-8B45-ECE2F6AEBF45Q28078976-4CBBCBD9-3A89-4E01-8C1C-D60897A2A9C0Q28118456-3660278E-9B34-43EB-9D41-F9222BDB88FBQ28118787-920A64CB-910A-4CCC-BA6A-1537137840B3Q28534831-9F8DF1E0-59B1-4378-8471-EBF8A0D2100CQ28569097-CC1A48B3-A506-4284-8279-F181B24A4AE9Q28571377-7A7CAFA2-D81D-4FA6-B5F2-CB5EE1B18185Q28572271-3A6C5898-D77F-4FDC-BEBD-62FCD8CF81FCQ28578858-B3A2B8EC-4220-4C76-AFBF-352C8BFED3B0Q28590362-272D4CE4-A7A0-45CE-8DF7-3298DBD658A2Q30544892-61E85FB5-658E-4250-8148-AF50A563CBF7Q30583630-3B669653-E54E-43D0-9506-2B195A33BF54Q31047574-F5E4BB27-D3EF-440D-AA78-05A557233982Q32884516-1A97AD50-3DBE-448D-854A-AF02CF2A0514Q33265315-C1542273-1F35-4ED4-BB78-0B0A22478E43Q33685088-5F6298B1-007A-4692-820E-3508088769EAQ33784417-6817210A-5F4D-4B43-ADFC-C288CDDE22C4Q33898213-80D36F11-CA16-4E6E-8639-3E130948B0F5Q33915567-D4F2DFA5-90A2-4F92-B4DE-E2FE55DBABE1Q34059841-A8B4A406-A006-4773-8B4C-EC76A1184384Q34215319-04F54FE8-A0E1-473B-8F14-C35962128019Q34293026-94D1E194-7146-4751-BA02-9581676C703BQ34402401-693A7328-F5EA-4502-9DA6-04F3A32E77DCQ34468421-9B1CFDDE-8C4B-42C6-BB03-3A0B645CD2A4Q34589929-B626A25D-A5A6-4BC6-AD8A-9C4CCFD98FCAQ34782588-4E82D421-DB42-48B1-8D18-3C5C5D051680Q34903204-BFACA6E0-FF26-45DB-89C7-2AB876E86D56Q34958933-1BC6A0E1-936B-4387-82DB-01030BDC9CB5Q35024562-D3CF132F-F587-437A-ADE7-A5E41D05A07F
P2860
Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Primary pulmonary hypertension ...... orphogenetic protein receptor.
@en
Primary pulmonary hypertension ...... orphogenetic protein receptor.
@nl
type
label
Primary pulmonary hypertension ...... orphogenetic protein receptor.
@en
Primary pulmonary hypertension ...... orphogenetic protein receptor.
@nl
prefLabel
Primary pulmonary hypertension ...... orphogenetic protein receptor.
@en
Primary pulmonary hypertension ...... orphogenetic protein receptor.
@nl
P2093
P50
P1433
P1476
Primary pulmonary hypertension ...... orphogenetic protein receptor.
@en
P2093
Carl Atkinson
Jennifer R Thomson
Paul D Upton
Susan Stewart
P304
P356
10.1161/01.CIR.0000012754.72951.3D
P407
P577
2002-04-01T00:00:00Z